@anubisbc.bsky.socialEndpoint News is honoring 20 women in #biopharma.
Women still make up a small percentage of upper leadership in the life sciences industry. That trend is changing: in 2026, about 12% of life sciences companies are led by women, up from 10.8% of CEOs in 2025.
@drtimos.bsky.social🧠 Competitive Insights for #BioPharma and #HealthTech 🚀
#LucidQuest arms #pharma & #biotech with real-time intel to outpace rivals from R&D to market.
📩 [email protected] or http://dlvr.it/TVxXLr
#CompetitiveIntelligence #Strategy #MarketAccess
@forbes.itFilippo Surace ha creato Cube Labs, venture builder quotato su Euronext Growth Milan con 19 startup nelle scienze della vita #biopharma #cube-labs #euronext-growth-milan #filippo-surace #forbes-italia #life-science #longevita #medtech #nutraceutica #pmi-2 #ricerca-e-innovazione #scienze-della-vit...
@pharmaphorum.bsky.socialRecent developments in the #biopharma #AI world include a $1.5 billion #partnership between #AstraZeneca and #insitro, plus news from Iambic, DaltonTx, NVIDIA, and Chai Discovery.
@newsramp.comQuantum BioPharma (NASDAQ: QNTM) receives FDA clearance to begin Phase 2 trials for Lucid-MS, a novel multiple sclerosis therapy that protects nerve cells by targeting myelin damage — not the immune system. A potentially distinct approach to MS treatment. #MultipleSclerosis #Biopharma
@leeasplund.bsky.socialWelcome to Wednesday Words, where I will define one word used in biotechnology or biopharma each Wednesday morning!
If you want to learn more, check out: sbee.link/6khrdw9c3e
@outsourcedpharma.bsky.socialRaw materials can look routine until they’re the reason production stops. Outsourced Pharma’s Deputy Editor examines five assumptions sponsors should challenge before variability, supplier changes or release delays derail a CDMO campaign.
www.outsourcedpharma.com/doc/five-raw...
@big4bio.comThe countdown to #BioFuture2026 is on. One week until 500+ industry leaders, 100+ speakers, and 50+ presenting companies gather in #NYC on October 27–28 to discuss the future of #biopharma.
🔗 Register: bit.ly/4vYXhJq
@scalanovahealth.bsky.social1. Strategy & NPI Ingestion
2. Zero-PHI AI Pods
3. 100% IP Transfer
4. Metrics: <30 day pod setup, 40-60% burn cut, <2hr campaign flip.
@itln.bsky.socialPharma air cargo needs tighter control at every handover
#pharmalogistics #aircargo #coldchain #biopharma #cellandgenetherapy #supplychainmanagement #temperaturecontrolledlogistics #gpls2026
@newsramp.comQuantum BioPharma (NASDAQ: QNTM) signs deal with Thermo Fisher to launch Phase 2 trial of Lucid-MS, a first-in-class neuroprotective therapy targeting progressive multiple sclerosis. FDA cleared the IND just two months ago. #MultipleSclerosis #Biopharma
@newsramp.comQuantum BioPharma (QNTM) signs a Study Start-Up Agreement with Thermo Fisher Scientific to launch a Phase 2 trial of Lucid-MS, a novel neuroprotective MS therapy targeting demyelination rather than immune suppression. #MultipleSclerosis #Biopharma
@newsramp.comSilo Pharma (NASDAQ: SILO) receives U.S. Patent Notice of Allowance for SPC-15, its intranasal PTSD therapeutic. A matching patent was already granted in Japan, strengthening Silo's global IP strategy as it advances development of this promising treatment. #PTSD #Biopharma
@newsramp.comQuantum BioPharma (NASDAQ: QNTM) is developing Lucid-MS, targeting the enzyme behind myelin destruction in MS patients. With ~3 million people affected globally and no approved therapy reversing neurodegeneration, this candidate could fill a critical gap. #MultipleSclerosis #Biopharma
@newsramp.comQuantum BioPharma (NASDAQ: QNTM) is developing Lucid-MS, targeting the enzyme behind myelin destruction in MS patients. With ~3 million people affected globally and no approved therapy reversing neurodegeneration, this candidate could fill a critical gap. #MultipleSclerosis #Biopharma
@newsramp.comQuantum BioPharma (NASDAQ: QNTM) has received FDA approval to advance Lucid-MS into phase 2 clinical trials for multiple sclerosis. The drug showed a strong safety profile in phase 1 and uses a distinct mechanism from existing MS therapies. #Biopharma #MultipleSclerosis
@newsramp.comQuantum BioPharma (NASDAQ: QNTM) receives FDA approval to advance Lucid-MS into Phase 2 clinical trials for multiple sclerosis. The drug showed a strong safety profile in Phase 1 and features a proprietary mechanism that sets it apart from existing therapies. #Biopharma #MultipleSclerosis
@newsramp.comQuantum BioPharma (NASDAQ: QNTM) signs Study Start-Up Agreement with Thermo Fisher Scientific to advance its Phase 2 trial of Lucid-MS, a first-in-class neuroprotective treatment for progressive multiple sclerosis. #MultipleSclerosis #Biopharma
@newsramp.comLantern Pharma (NASDAQ: LTRN) closes a $4M registered direct offering at $1.09/share, with warrants that could yield an additional $4M. Proceeds fuel its AI-driven precision oncology pipeline. #Biopharma #Oncology
@stattimes.bsky.socialHandover is the weak link in pharma air cargo
#pharmalogistics #aircargo #coldchain #biopharma #cellandgenetherapy #supplychainmanagement #temperaturecontrolledlogistics #gpls2026 #stattimes